Pegylated Interferon Alpha – 2a in Patients with Myeloproliferative Neoplasms (MPN): International Experience in 115 Cases
Krisstina Gowin(University of Arizona), Ruben A. Mesa(Atrium Health Wake Forest Baptist), J Samuelson(Karolinska Institutet), Claire Harrison(Guy's and St Thomas' NHS Foundation Trust), Casey L. O’Connell(University of Southern California), Björn Andréasson(NU Hospital Group), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), John Camoriano(WinnMed), Tiziano Barbui(University of Bergamo), John Mascarenhas(Tisch Hospital), Catherine Rea(St Thomas' Hospital), A Gentry(Mayo Clinic in Arizona), Jean‐Jacques Kiladjian(Délégation Paris 5), Prakash Thapaliya(WinnMed), Deepti Radia(St Thomas' Hospital)
Cited by 0
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k